Introduction
Faithful chromosome segregation is maintained by a mitotic spindle checkpoint, a surveillance mechanism that delays the onset of anaphase until all chromosomes have established bipolar attachment to the microtubules. Formation of a bipolar spindle is also essential for chromosome stability, because a numerical abnormality of the mitotic spindle poles leads to chromosome segregation errors, resulting in chromosome instability. Thus, to ensure accurate chromosome segregation in mitosis, eukaryotic cells employ a dynamic architecture of kinetochores, centrosomes and spindle microtubules (Nigg, 2002; Rieder and Khodjakov, 2003) .
The spindle attachment to kinetochore is robustly monitored by a mitotic spindle assembly checkpoint (Cleveland et al., 2003; Kops et al., 2005; Musacchio and Salmon, 2007) , which prevents chromosome segregation error by blocking the onset of anaphase until all chromosomes make proper attachments to mitotic spindles (Yu, 2002; Kops et al., 2005) . BubR1 is a central component of the spindle assembly checkpoint, which localizes to the kinetochore in early metaphase and prevents premature separation of sister chromatids. We and another group recently reported constitutional mutations of the BUB1B gene (encoding BubR1) in patients with premature chromatid separation (PCS) syndrome (Hanks et al., 2004; Matsuura et al., 2006) , also called mosaic variegated aneuploidy (MVA) syndrome. PCS syndrome is a rare autosomal recessive disorder characterized by premature separation of sister chromatids of all chromosomes in more than 50% of mitotic lymphocytes and a variety of mosaic aneuploidies, especially trisomies and monosomies (Kajii et al., 1998) . Infants with PCS syndrome show growth retardation, severe microcephaly and a high risk of malignancy, such as Wilms tumor and rhabdomyosarcoma (Kawame et al., 1999; Kajii et al., 2001; Plaja et al., 2001; Jacquemont et al., 2002) . We previously reported that the cultured skin fibroblasts from two unrelated infants with PCS syndrome showed defects in the spindle assembly checkpoint (Matsuura et al., 2000) . Consequently we identified monoallelic BUB1B mutations in seven families with PCS syndrome (Matsuura et al., 2006) . In each of these seven families there was one mutation that resulted in premature protein truncation or functional debilitation of the gene product. Although no second mutation was found in the allele opposite the one in which a mutation was detected, the number of transcripts of the second allele was moderately reduced. Thus, the cells in the patients show >50% decrease in the expression of BubR1 protein (Matsuura et al., 2006) .
Here, we report that PCS syndrome cells show severe chromosome instability not only because of the mitotic checkpoint defect but also because of the centrosome amplification. We also show that Polo-like kinase 1 (Plk1) activity is upregulated in PCS syndrome cells, and ectopic expression of BubR1 restores abnormal phenotypes of centrosome amplification in PCS syndrome cells. Thus, BubR1 deficiency causes centrosome amplification as well as spindle assembly checkpoint defect. Moreover, BubR1 localizes to centrosomes, physically interacts with Plk1 and inhibits Plk1 phosphorylation and its kinase activity during interphase. These results suggest that centrosomeassociated BubR1 shields Plk1 from unscheduled activation during interphase. Thus, these results unravel a novel role of BubR1 in preventing centrosome reduplication through negative regulation of Plk1 in interphase cells.
Results

PCS syndrome cells show severe chromosome instability because of multipolar mitosis
We first carried out a precise chromosome analysis of the patient's lymphoblastoid cell line (LCL). The lymphoblastoid cells from a normal individual (TO) showed no increase in aneuploidy (Figures 1a and b) , whereas mosaic aneuploidy including trisomies and monosomies was observed in 80% of a PCS patient's cells (MY1L; Figure 1c ). This observation could reflect the inaccurate chromosome segregation in mitosis because of BubR1 deficiency (Baker et al., 2004; Hanks et al., 2004) . In addition, a small fraction (20%) of the Immunoblot of anti-atubulin antibody served as a loading control. (f) Representative image of cytokinesis in a normal lymphocyte. Centrosome was stained with anti-g-tubulin antibody (red). Cytoplasm was stained with anti-Polo-like kinase 1 (Plk1) antibody (green). DNA was stained with 4 0 ,6-diamidino-2-phenylindole dihydrochloride (DAPI; blue). Scale bar, 10 mm. (g) Representative image of multipolar mitosis (cytokinesis) in a PCS lymphocyte. Scale bar, 10 mm. (h) The proportion of cells with multipolar mitosis in normal lymphocytes (TO) and PCS lymphocytes (MY1L). Approximately 17% of cells showed multipolar mitosis in PCS lymphocytes. For each cell line, X100 cells were examined. The data are shown as average±standard error determined from three separate experiments. (i) BubR1 expression was reduced in the fibroblasts from two unrelated PCS patients (MY1 and PCS1) compared to normal control fibroblasts (KM). Immunoblot of anti-a-tubulin antibody served as a loading control. (j) Representative image of mitosis in normal fibroblast cells (KM). Centrosomes were stained with anti-g-tubulin antibody (red). Kinetochores were stained with anti-BubR1 antibody (green). DNA was stained with DAPI (blue). Scale bar, 10 mm. (k and l) Representative images of multipolar mitosis in two fibroblast cell lines from PCS syndrome patients (MY1 and PCS1). Scale bars, 10 mm. (m) The frequency of cells with multipolar mitosis in PCS syndrome fibroblasts. For each cell line, X100 cells were examined. The data are shown as average ± standard error determined from three separate experiments.
BubR1 prevents Plk1 activity on centrosome H Izumi et al MY1L cells was aneuploid with a chromosome number less than 40 (Figures 1c and d) . Such severe aneuploidy was not observed in the control cells. We inferred that these severely aneuploid cells with chromosome number o40 were not due to the spindle assembly checkpoint defect but due to abnormal mitosis such as multipolar mitosis. We therefore analysed the mitotic cells by immunostaining. The PCS lymphoblastoid cells (MY1L), in which BubR1 expression was reduced (Figure 1e ), showed 17% of cells in multipolar mitosis with abnormal numbers of centrosomes ( Figures  1g and h ). On the other hand, the cells from a normal control (TO) showed no increase in aberrant mitosis (Figures 1f and h ). The immortalized fibroblast cells (termed MY1 and PCS1) from two unrelated patients with PCS syndrome (Figure 1i ) also exhibited an increase in multipolar mitosis with abnormal numbers of centrosomes, similar to those in the lymphoblastoid cells, MY1L (Figures 1j-m) . Thus, PCS syndrome cells have an abnormal number of centrosomes in mitosis.
Centrosome duplication machinery was deregulated in PCS syndrome cells To analyse whether PCS syndrome cells already have abnormal numbers of centrosomes in interphase, we performed immunostaining experiments using anti-gtubulin and anti-centrin 2 antibodies. PCS lymphocytes had an increased number of centrosomes in interphase (Figures 2c and d) , whereas normal lymphocytes did not show such a phenotype (Figures 2a and b) . We next examined the fibroblast cells from the two patients. Most of the fibroblast cells from a normal individual (termed KM) had one or two centrosomes (two or four centrioles, respectively) in interphase, and the frequency of centrosome amplification (three or more centrosomes) was only 3% (Figures 2e and h ). In contrast, the fibroblasts from the two patients (MY1 and PCS1) showed centrosome amplification ( Figures  2f-h ). Centrosome fragmentation was not observed in either the control cells or the PCS syndrome cells because centrin staining (a marker for individual centrioles) showed two spots for every one g-tubulin spot (Figures 2e-g ).
We next examined whether excessive duplication of centrosomes in PCS syndrome cells was due to loss of regulation of the centrosome duplication machinery. Hydroxyurea (HU), a DNA synthesis inhibitor, arrests the cell cycle at the G 1 -S transition and allows centrosome duplication but not centrosome reduplication in normal human cells. However, if the centrosome duplication machinery is deregulated, centrosome reduplication (centrosome amplification) is induced with prolonged HU exposure (Balczon et al., 1995) . We therefore exposed HU to the normal cells and PCS syndrome cells, and the cells were examined by immunostaining. In the normal cells, only a low level of centrosome reduplication was detected following HU treatment (Figure 2i ), demonstrating that centrosome duplication was tightly regulated with DNA synthesis. On the other hand, the frequency of centrosome reduplication was increased in PCS syndrome cells (Figure 2i ), suggesting that the centrosome duplication machinery is deregulated in PCS syndrome cells (see Supplementary Movies S1 and S2).
BubR1 localizes to centrosomes and suppresses centrosome amplification
To examine the role of BubR1 in centrosome function, we transferred into PCS1 cells a whole chromosome 15 (Ch.15) or the minimal chromosomal segment (BubR1), both of which contain the BUB1B locus, and analysed their centrosome profiles and multipolar mitosis ratio. The chromosome-transferred PCS1 cells showed normal expression level of BubR1 ( Figure 3a) and restoration of abnormal number of centrosomes (Figures 3b and c) and multipolar mitosis (Supplementary Figure S1 ). These results suggest that BubR1 is somehow involved in centrosome functions. Therefore, we examined subcellular localization of BubR1 in normal cells (KM). Interestingly, BubR1 localized to centrosomes in interphase cells, but such a signal was not seen in mitotic spindle poles (Figures 3d and e) . Centrosomal localization of BubR1 was also seen in the other cell lines we examined, such as HeLa cells (Supplementary Figure S2 ) and HCT116 cells (data not shown). To examine whether such BubR1 signals show a genuine centrosomal component, we carried out centrosomal fractionation analysis using normal cells. BubR1 was included in interphase g-tubulin fractions but not in mitotic g-tubulin fractions To determine the BubR1 domain for centrosome localization, we constructed several green fluorescent protein (GFP)-fused BubR1 deletion mutants, transfected them into normal cells and analysed their centrosome localizations. The full-length BubR1 (wild type), N-terminal deletion mutant (DN), C-terminal deletion mutant (DKinase) and kinase-dead mutant with K795R (KD) were able to localize to the centrosomes (Figure 3k ; Supplementary Figure S4 ). On the other hand, the deletion mutant of kinase only was not able to localize. These results suggest that the central region of BubR1 (residues 240-639) is important for centrosomal localization. We then transfected these deletion mutants into PCS1 cells and analysed the number of cells with three or more centrosomes. The PCS1 cells transfected with the mutants that were able to localize to centrosomes showed restoration of an abnormal number of centrosomes ( Figure 3k ). On the other hand, the cells transfected with the mutant of kinase only that was not able to localize to centrosomes did not show such a restoration ( Figure 3k ).
PCS syndrome cells have high Plk1 activity on centrosomes
To explore the mechanism of centrosome amplification by BubR1 deficiency, we examined the expression levels of several centrosomal proteins, including Plk1, Plk4, Aurora-A and p53, by immunoblotting ( Figure 4a ). The expression levels of p53 and Aurora-A did not change when compared with those of control cells. Flow cytometry analyses also showed that these cell lines have similar cell-cycle profiles (data not shown). Plk4 expression was slightly decreased in PCS syndrome cells. Conversely, we found that the phosphorylated form of Plk1 was higher in PCS syndrome cells (Figure 4a ). The transfer of chromosome 15 normalized the increased band intensities of the phosphorylated form of Plk1 ( Figure 4a ). As it has been reported that the phosphorylation of threonine residue 210 of Plk1 is well correlated with Plk1 activity (Barr et al., 2004; van Vugt and Medema, 2005) , our results suggest that Plk1 activity is upregulated in PCS syndrome cells. Therefore, we addressed Plk1 activity in PCS syndrome cells by an in vitro kinase assay ( Figure 4b ). The Plk1 substrate GST-Cdc25C (Barr et al., 2004; van Vugt and Medema, 2005) was added to the immunoprecipitates by anti-Plk1 antibody. We found that the serine residue (Ser198) in GST-Cdc25C was highly phosphorylated in PCS1 cells as compared to that of the control cell lines, suggesting that PCS syndrome cells have high Plk1 activity, and that the increased phosphorylated form of Plk1 reflects Plk1 activity (Toyoshima-Morimoto et al., 2002) .
To further confirm that phospho-Plk1 (active Plk1) localizes to centrosomes, we carried out additional centrosomal fractionation analysis using normal cells, PCS1 cells and PCS1-BubR1 cells. We also examined the immunoblots of total cell lysates in addition to that of their centrosome fractions. Both proteins were included in the major peak of g-tubulin fractions of normal cells, which is direct evidence that BubR1 and phospho-Plk1 are genuine centrosomal components ( Figure 4c ). It was also found that an especially high amount of phospho-Plk1 was included in the g-tubulin fractions from PCS1 cells. These results support that PCS syndrome cells have high Plk1 activity on centrosomes. It was also found that the band intensity of BubR1 in the g-tubulin fractions was not as high as that in the total cell lysate. These results suggest that only a small fraction of the total BubR1 pool localizes to centrosomes and the remaining larger BubR1 pool distributes around cytoplasm during interphase. Although Plk1 localizes to centrosomes throughout interphase, Plk1 has a maximum activity around G 2 -M phases. Thus, active Plk1 was localized to duplicated centrosomes. To investigate centrosomal Plk1 activity during cell cycle in PCS syndrome cells, we used antiphospho-Plk1 antibody for immunostaining of centrosomes. Our immunofluorescent studies showed that, in normal cells, active Plk1 signal did not detect the immature, unduplicated centrosomes, but detected duplicated centrosomes (Figures 4d-f) . On the other Green fluorescent protein (GFP) alone, and GFP-kinase did not localize to centrosomes. Full-length, DN, DKinase and KD (kinasedead) mutant proteins were able to localize to the centrosomes. These results suggest that residues 240-639 of BubR1 are necessary for the centrosomal localization of BubR1. These deletion mutants were also transfected into PCS1 cells, and the ratio of centrosome amplification was determined by immunostaining. For each transfectant, X50 cells were examined. The data are shown as an average of three separate experiments. 
BubR1 physically interacts with Plk1
The functional relationship between BubR1 and Plk1 suggests a physical interaction of these proteins. To examine whether BubR1 interacts with Plk1, we performed an immunoprecipitation experiment using anti-BubR1 and anti-Plk1 antibodies. BubR1 was detected in the immunoprecipitates by using anti-Plk1 antibody (Figure 5a) , and, conversely, Plk1 was detected in the immunoprecipitates using anti-BubR1 antibody in asynchronously growing cells (Figure 5b ). These results suggest that endogenous BubR1 interacts with Plk1 in vivo.
To determine which domain of BubR1 interacts with Plk1, GFP-BubR1 deletion mutants were transfected into HeLa cells and analysed by immunoprecipitation experiments using anti-Plk1 antibody. The mutant BubR1 constructs are shown in Figure 3k . The fulllength proteins, DN and DKinase were found to be coimmunoprecipitated with endogenous Plk1, whereas the N-terminal deletion mutant (kinase only) did not coimmunoprecipitate with Plk1 (Figure 5c ). These results suggest that the internal region (residues 240-639) of BubR1 is necessary for forming a complex with Plk1 in vivo.
To determine the domain of Plk1 that interacts with BubR1, we transfected a Flag-Plk1 wild-type or a Flag-Plk1 Polo-box inactive mutant (Flag-Plk1 H538A/K540M) into HeLa cells and carried out immunoprecipitation experiments using anti-Flag antibody. Flag-Plk1 formed a complex with endogenous BubR1, whereas the Flag-Plk1 Polo-box inactive mutants showed a reduced association with BubR1 (Figure 5d ). These results suggest that the Polo-box domains of Plk1 are important for forming a complex with BubR1 in vivo. We also examined in vitro immunoprecipitation experiment by using GST-BubR1 and His-Plk1 proteins (Figure 5e ). GSTBubR1 directly bound to His-Plk1, suggesting that BubR1 physically interacts with Plk1 in vitro.
We showed in Figures 3k and 5c that the BubR1 deletion mutant, which were not able to interact with Plk1, did not localize to centrosomes. These results suggest that Plk1 may be necessary for BubR1 to localize to centrosomes. Therefore, we carried out Plk1 depletion in HeLa cells by siRNA and analysed centrosomal localization status of BubR1 in interphase (Figure 5f ). Control siRNA-treated cells showed high intensities of BubR1 signals on centrosomes (Figures 5g  and h ). On the other hand, the Plk1-knockdown cells showed almost abolished signal intensities of BubR1 on centrosomes (Figures 5g and h) . We also examined this experiment in the presence of HU, and we obtained similar result (data not shown). These results show that Plk1 is necessary for BubR1 to localize to centrosomes in interphase cells (Supplementary Figure S3B) .
BubR1 negatively regulates Plk1 activity in interphase cells
To evaluate how BubR1 affects Plk1 function, we constructed a tetracycline (Tet)-inducible BubR1 expression vector and transfected it into the PCS syndrome cells (PCS1). The stably transfected cells were synchronized into interphase with HU in the presence or absence of Tet, and after 48 h the cells were lysed and examined by immunoblotting. The induced expression of BubR1 suppressed Plk1 activity in interphase cells (Figure 6a) . Moreover, the induced expression of BubR1 suppressed centrosome amplification (Supplementary Figure S5) . Conversely, we established a stable BubR1-knockdown HCT116 cell line (a colorectal cell line without chromosome instability (Cahill et al., 1998) ) by siRNA vector and examined Plk1 activity and centrosome number. The BubR1-knockdown cells showed increased Plk1 activity (Figure 6b) , and also showed increased centrosome amplification and multipolar mitosis as compared to control cells (Supplementary Figure S6 ). We showed in Figure 3k that two BubR1 mutants (a deletion mutant lacking the kinase domain (DKinase), and a kinase-dead mutant with K795R substitution) were able to localize to centrosomes and suppress centrosome amplification in PCS1 cells, suggesting that the kinase activity of BubR1 is not necessary for suppression of Plk1. We then used a Plk1 Polo-box inactive mutant that was not able to interact with BubR1 and transfected it into asynchronous HeLa cells. The Plk1 Polo-box inactive mutant showed an increase in Plk1 phosphorylation as compared with the wild-type Plk1 (Figure 6c ). These results suggest that binding of Plk1 with the inhibitor (possibly BubR1) BubR1 prevents Plk1 activity on centrosome H Izumi et al is necessary for suppression of Plk1 phosphorylation in interphase. To test this idea, recombinant BubR1 was subjected to an in vitro kinase assay (Figure 6d ). Increasing amounts of GST-BubR1 full-length peptide or GST-BubR1 (240-639) peptide inhibited phosphorylation of GST-Cdc25C by His-Plk1 in vitro, whereas only GST peptide did not show such an inhibition. These results suggest that BubR1 binds to Plk1 and inhibits phosphorylation of Plk1 substrate. Next, we immunoprecipitated BubR1 from interphase lysate and from mitotic lysate, respectively. After that, in vitro Plk1 kinase assay was performed (Figure 6e ). As a control, immunoprecipitate with preimmune mouse immunoglobulin-G (IgG) was used. The immunoprecipitates were then subjected to immunoblotting using anti-BubR1 antibody. (b) Conversely, cell lysates were immunoprecipitated with anti-BubR1, and the immunoprecipitates were subjected to immunoblotting using anti-Plk1 antibody.
GST-Cdc25C
(c) Several GFP-BubR1 deletion mutants were transfected into HeLa cells, and after 48 h, cells were harvested and lysed. The cell lysate was immunoprecipitated using anti-Plk1 antibody, and the immunoprecipitate was then subjected to immunoblotting using anti-GFP antibody. (d) Flag-Plk1 or Flag-Plk1 H538A/K540M was transfected into HeLa cells, and at 48 h after transfection, the cells were harvested and lysed. The cell lysates were immunoprecipitated using anti-Flag antibody, and the immunoprecipitates were then subjected to immunoblotting using anti-BubR1 antibody. (e) BubR1 directly binds to Plk1 in vitro. His-Plk1 was incubated with GST or GST-BubR1 for 2 h. The incubate mixture was immunoprecipitated with anti-GST antibody, and the immunoprecipitates was subjected to immunoblotting by anti-Plk1 antibody. 
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Although the immunoprecipitated-BubR1 was highly phosphorylated from mitotic sample, interphase BubR1 was not from interphase lysate. Plk1 kinase assay showed that the kinase activity of Plk1, which interacted with interphase BubR1, was basal level (Figure 6e ). On the other hand, the kinase activity of Plk1, which interacted with mitotic BubR1, was extraordinarily high level, even when Plk1 protein level was compensated (Figure 6f ). These results suggest that Plk1 activity is dependent on the phosphorylation status of BubR1. We then constructed a BubR1 deletion mutant (BubR1DPlk1) lacking the Plk1-binding domain (residues 240-639), which was not able to interact with Plk1, and transfected it into PCS1 cells. Plk1 activity was examined by in vitro kinase assays. The BubR1 deletion mutant was not able to suppress high Plk1 activity in PCS1 cells, whereas the full-length BubR1 could suppress Plk1 activity efficiently (Figure 6g ). It was also found that the deletion mutant was not able to suppress centrosome amplification in PCS1 cells (Figure 6h ).
The knockdown of Plk1 suppresses centrosome amplification in PCS syndrome cells As Plk1 was upregulated in PCS syndrome cells, we analysed whether the knockdown of Plk1 influences centrosome amplification in PCS syndrome cells. After 72 h of siRNA-mediated Plk1 depletion, we examined the centrosome profile in these PCS1 cells (Figure 7a ). The knockdown of Plk1 suppressed centrosome amplification in PCS1 cells (Figure 7b , left panel). As it is possible that cells with multiple centrosomes could arise as a result of cytokinetic failure, we carried out immunostaining experiment under HU-treated conditions. Control siRNA-treated cells showed high rate of centrosome amplification. On the other hand, the knockdown of Plk1 also suppressed centrosome amplification in PCS1 cells (Figure 7b , right panel). Thus it is likely that Plk1 is directly involved in centrosome amplification in PCS syndrome cells.
Overexpression of Plk1 directly induces centrosome amplification in interphase cells
To examine whether overexpression of Plk1 directly induces centrosome amplification, the Plk1 expression vector with H2B-GFP as a transfection marker was cotransfected into HeLa cells (Figure 7c) , and H2B-GFP-positive cells were examined. In addition, we prepared BubR1-knockdown HeLa cells transfected with Plk1 expression vector and H2B-GFP (Figure 7c ; HeLa-Plk1/H2B-GFP/BubR1i). It was reported previously that overexpression of Plk1 induces a defect in cytokinesis, resulting in the accumulation of binucleated cells (Meraldi et al., 2002) . Consistent with this, we observed binucleated cells after overexpression of Plk1 (Figure 7d) . However, the frequency of binucleated cells was only 12%, and the remaining cells (88%) were mononucleated ( Figure 7d ). Similar result was obtained in BubR1-knockdown HeLa cells transfected with Plk1 expression vector and H2B-GFP (Figure 7d ). We therefore examined the centrosome profile in H2B-GFPpositive, mononucleated cells. Overexpression of Plk1 dramatically induced centrosome amplification (35%) and multipolar mitosis (40%; Figures 7e, f; Supplementary Figure S7A ) in spite of HeLa cells having tight centriole duplication machinery (Loncarek et al., 2008) . Moreover, overexpression of Plk1 plus knockdown of BubR1 enhances more dramatically induced centrosome amplification (47%) and multipolar mitosis (52%; Figures 7e and f) . When these cells were treated with HU, the frequency of centrosome amplification was markedly increased (Figures 7g; Supplementary Figure  S7B ), suggesting that overexpressed Plk1-mediated centrosome amplification is induced during interphase and that BubR1 suppresses centrosome amplification activity of Plk1.
Discussion
We found that centrosome amplification and multipolar mitosis result in severe chromosome instability in PCS syndrome cells. We also found that the frequency of centrosome amplification increases after HU treatment. These results suggest that PCS syndrome cells have lost the ability to regulate the centrosome duplication machinery. PCS syndrome cells showed increased activity of Plk1, whose knockdown suppressed centrosome amplification. BubR1 localized to centrosomes and negatively regulated Plk1 activity in normal interphase cells. These results suggest that BubR1 prevents centrosome amplification, one mechanism of which is negative regulation of Plk1. Centrosomes serve as the microtubule-organizing center and play a critical role in organizing the bipolar mitotic spindle. It has been reported that Plk1 is involved in maturation, separation and duplication of centrosomes (Lane and Nigg, 1996; Liu and Erikson, 2002; Barr et al., 2004; van Vugt and Medema, 2005) . Plk1 localizes to the centrosome during interphase, but its activity is suppressed until early M phase (Golsteyn et al., 1995) . We showed that overexpression of Plk1-mediated centrosome amplification is induced by centrosome reduplication during interphase, and the contribution of cytokinesis failure is not as great as reported previously (Meraldi et al., 2002) . These findings suggest that Plk1 activity is strictly regulated during the cell cycle, and Plk1 executes the centrosome reduplication function when prematurely activated before early M phase.
BubR1 protein contains several functional domains: a highly conserved domain with MAD3 homology at the N terminus, a Bub3-binding domain and a Cdc20-binding domain in the central region and a kinase domain at the C terminus. We found that the central region is necessary for centrosomal localization of BubR1 and for suppression of centrosome amplification in PCS syndrome cells, and that BubR1 interacts with Plk1 in this region, which overlaps with the region for centrosomal localization.
BubR1 prevents Plk1 activity on centrosome H Izumi et al Two possibilities are conceivable for the mechanism by which BubR1 suppresses Plk1 activity. The first is that BubR1 phosphorylates Plk1 and inactivates it. The second is that BubR1 simply binds to Plk1 and directly inhibits its phosphorylation and kinase activity of Plk1. We showed that both the GFP-BubR1 deletion mutants lacking the kinase domain and the BubR1 kinase-dead mutant were able to localize to centrosomes and suppress centrosome amplification in PCS syndrome cells. We therefore conclude that the first possibility is unlikely. We then examined the second possibility and analysed a Plk1 Polo-box inactive mutant that was not able to interact with BubR1. The Plk1 mutant showed a substantial increase in autophosphorylation, as has been suggested previously (Lee and Erikson, 1997; Mundt et al., 1997) . These results strongly suggest that binding of the Polo-box domain with its inhibitor (possibly BubR1) is necessary for Plk1 suppression in interphase.
In fact, in vitro kinase assay showed that BubR1 inhibited phosphorylation of GST-Cdc25C by Plk1. From this finding, it is likely that BubR1 simply binds to Plk1 and sequesters it from substrates. Moreover, we examined an in vitro kinase assay using the BubR1 deletion mutant that lacks the Plk1-binding domain (BubR1DPlk1). This deletion mutant was not able to suppress high Plk1 activity in PCS syndrome cells, whereas full-length BubR1 could suppress Plk1 activity considerably. It was also found that this deletion mutant was not able to suppress centrosome amplification in PCS syndrome cells. These results strongly suggest that BubR1 binds to the Polo-box domain on Plk1 and prevents Plk1 from premature activation. Moreover, we examined immunoprecipitation-combined in vitro kinase assay whether the interphase BubR1 was biochemically different from the mitotic BubR1. Our results showed that Plk1 activity was correlated with the phosphorylation status of BubR1, suggesting that BubR1 function is controlled by phosphorylation. During G 2 -M transition, BubR1 is phosphorylated by the priming kinase, Cdk1/ Cyclin B (Elowe et al., 2007; Matsumura et al., 2007) . The phosphorylated BubR1, in turn, acts as a spindle assembly checkpoint component on kinetochore. This regulation must be an important event for function of BubR1 during cell cycle. That is, the interphase nonphosphorylated BubR1 acts as an inhibitor of Plk1 on centrosome and prevent premature activation of Plk1. During G 2 -M transition, once BubR1 is phosphorylated by Cdk1 kinase, the phosphorylated-BubR1 may dissociate from centrosomes, and Plk1 may be easily activated by Aurora-A/Bora system (Macurek et al., 2008; Seki et al., 2008) and/or autophosphorylation. Thus, BubR1 may be a bifunctional protein: BubR1 prevents premature activation of Plk1 in interphase, whereas BubR1 acts as a spindle assembly checkpoint complex with Plk1 in mitosis (Figure 8 ). BubR1 was initially identified as a spindle assembly checkpoint protein; it generates the 'wait anaphase' signal by binding to and inhibiting Cdc20, a specific activator of the anaphase-promoting complex/cyclosome (APC/C). Recently, Oikawa et al. (2005) reported an indirect role of BubR1 in the suppression of centrosome amplification in mouse cells lacking p53. They found that exogenous expression of BubR1 eliminated mouse p53À/À cells with amplified centrosomes by inducing mitotic cell death via execution of the mitotic spindle checkpoint (Oikawa et al., 2005) . These results show that the mitotic spindle checkpoint may be an eliminator of any mitotic cells with amplified centrosomes. Alternatively, amplified centrosomes initially form multipolar spindle, but these spindles ultimately become bipolar. This phenomenon required a delay in mitosis that is mediated by mitotic spindle checkpoint in several culture conditions (Chiba et al., 2000; Basto et al., 2008) . On the other hand, in this study, we found that BubR1 has an additional role in the suppression of centrosome amplification: BubR1 shields Plk1 activity with physical and functional binding on centrosomes in interphase cells. Thus, in PCS syndrome cells, high Plk1 activity due to BubR1 deficiency contributes to centrosome amplification.
PCS syndrome is a rare autosomal recessive disorder with a high risk of malignancy, including Wilms tumor (Kawame et al., 1999; Kajii et al., 2001; Plaja et al., 2001; Jacquemont et al., 2002) . We examined centrosome status in Wilms tumor tissue derived from a PCS syndrome patient. A high degree of centrosome Immunoblot of anti-a-tubulin antibody was used as a loading control. (c) BubR1 interacts with Plk1 and suppresses phosphorylation of Plk1. Flag-Plk1 or Flag-Plk1 H538A/K540M was transfected into HeLa cells, and at 48 h after transfection, the cells were harvested and lysed. The cell lysates were immunoprecipitated using anti-Flag antibody, and the immunoprecipitates were then subjected to immunoblotting using anti-Plk1-T210-P and anti-BubR1 antibodies. (d) In vitro kinase assay of Plk1 in the presence of BubR1 or BubR1-deletion mutant (240-639a. a.). His-Plk1 (400 ng) was incubated with 1 mg of GST-Cdc25C in the presence or absence of GSTBubR1, 50, 100, 200 ng) . After incubation at 30 1C for 30 min, the sample was subjected to immunoblotting by anti-phospho-Cdc25C (Ser198-P) antibody. BubR1 inhibits phosphorylation of Plk1 substrate in vitro. (e) In vitro kinase assay of GST-Cdc25C by Plk1 in the anti-BubR1 immunoprecipitates from HU-treated cell lysates or nocodazole-treated cell lysates. The immunoprecipitates were subjected for the in vitro kinase assay of GST-Cdc25C. The reaction products were analysed by immunoblotting using anti-phospho-Cdc25C (Ser198-P) antibody. (f) The quantitative analysis of Ser198-P signal intensity when Plk1 protein level was compensated. (g) In vitro phosphorylation assay of GST-Cdc25C by Plk1 in PCS1 transfectants. GST-Cdc25C was incubated with anti-Plk1 immunoprecipitates from the indicated transfectants in the presence of ATP. The reaction products were analysed by immunoblotting using anti-phospho-Cdc25C (Ser198-P) antibody. The anti-Plk1 immunoprecipitates from the indicated transfectants were also subjected to immunoblotting using anti-BubR1 antibody. Immunoblot analysis of exogenous BubR1 expression in PCS1 transfectants (right panel; 10% input). (h) Centrosome profile of PCS1 transfectants. The transfected cells were examined for immunostaining by using anti-g-tubulin antibody. For each transfectant, X100 cells were examined. The data are shown as average±standard error determined from three separate experiments. BubR1 prevents Plk1 activity on centrosome H Izumi et al amplification was observed in the tumor tissue (Supplementary Figure S8 ). These findings suggest that centrosome amplification might contribute to chromosome instability and influence tumor formation in PCS syndrome.
In conclusion, PCS syndrome is a 'centrosome dysfunctional syndrome', in addition to the spindle checkpoint defect, and our findings reveal a crucial role for BubR1 in preventing centrosome amplification through negative regulation of Plk1.
Materials and methods
Cell lines and cell culture Epstein-Barr virus-transformed LCLs were cultured in RPMI1640 with 10% fetal bovine serum (FBS). Control LCL (TO) was established from a normal individual, and PCS syndrome LBL (MY1L) was from a patient described previously (Patient 2; Matsuura et al., 2006) . For metaphase preparation, LCLs were arrested for 3 h with 0.4 mg/ml of colcemid, treated at 32 1C for 20 min in 0.075 M KCl, and fixed in acetic acid/methanol (1:3). Chromosomes were spread onto glass slides at room temperature under 50-55% ambient humidity and stained with 4% Giemsa stain. Immortalized cell lines were established by transfecting primary cultured fibroblasts with phTERT retrovirus vector (Carney et al., 2002) . A control cell line (KM) was established from a normal individual, and PCS syndrome cell lines (MY1 and PCS1) were from two patients (Patient 2 and Patient 1, respectively; Matsuura et al., 2006) . HCT116 and HeLa cell lines were obtained from ATCC (Manassas, VA, USA). All of these cell lines were maintained in Dulbecco's modified Eagle's medium supplemented with 10% FBS in an atmosphere containing 5% CO 2 . Mouse hybrid cell line GM11715 containing human chromosome 15 was obtained from the NIGMS Human Genetic Mutant Cell Repository, and microcell-mediated chromosome transfer was performed as described previously (Matsuura et al., 1997) .
For remaining materials and methods, see Supplemental information on line.
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